Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP: MYCOF )

0.0053 -0.0016 (-23.19%)
Streaming Delayed Price Updated: 1:09 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mydecine Innovations Group Inc

< Previous 1 2 3 4 5 6 7 Next >
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Financing to Provide Runway for Key Milestones
Via Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland
Via Investor Brand Network
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CEO Discusses Blockbuster Drug Potential on MidasLetter Podcast
Via Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Featured in ROTH Equity Research Report
Via Investor Brand Network
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) (FSE: 0NF... 
Via Benzinga
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CMO to Participate in Horizons’ Veterans & Families Forum
Via Investor Brand Network
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event
Via Investor Brand Network
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
Via Investor Brand Network
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100. Beck&rsq... 
Via Benzinga
Topics Death
Exposures Death
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Patent Covering Formulations Featuring Nanoemulsion
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelics Offer Hope for Mental Disorders, Addiction
Via Investor Brand Network
BioMedNewsBreaks – Why Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Is ‘One to Watch’
Via Investor Brand Network
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation in November Event
Via Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Successfully Synthesizes Novel Psilocin Analogue
Via Investor Brand Network
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
The National Institutes of Health awarded a nearly $4 million grant meant to fund research on psilocybin, the act... 
Via Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
September Summary: Cannabis-Based Vs. Psychedelic Compounds-Based Drug Stock Performances
Which index out-performed in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index? 
Via Talk Markets
Psychedelics Called the ‘Next Frontier’ for Investors, Also Offer Promising Treatments
Via Investor Brand Network
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the... 
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.